Literature DB >> 11433311

Pathway specificity for Met signalling.

P M Comoglio.   

Abstract

Mesh：

Substances：

Year:  2001        PMID： 11433311     DOI： 10.1038/35083116

Source DB:  PubMed          Journal:  Nat Cell Biol        ISSN： 1465-7392            Impact factor:   28.824


× No keyword cloud information.
  25 in total

1.  Functional map and domain structure of MET, the product of the c-met protooncogene and receptor for hepatocyte growth factor/scatter factor.

Authors:  Ermanno Gherardi; Mark E Youles; Ricardo N Miguel; Tom L Blundell; Luisa Iamele; Julian Gough; Abhishek Bandyopadhyay; Guido Hartmann; P Jonathan G Butler
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-03       Impact factor: 11.205

Review 2.  Role of MetMAb (OA-5D5) in c-MET active lung malignancies.

Authors:  Mosmi Surati; Premal Patel; Amy Peterson; Ravi Salgia
Journal:  Expert Opin Biol Ther       Date:  2011-12       Impact factor: 4.388

3.  A direct role for Met endocytosis in tumorigenesis.

Authors:  Carine Joffre; Rachel Barrow; Ludovic Ménard; Véronique Calleja; Ian R Hart; Stéphanie Kermorgant
Journal:  Nat Cell Biol       Date:  2011-06-05       Impact factor: 28.824

4.  Met-HGF/SF signal transduction induces mimp, a novel mitochondrial carrier homologue, which leads to mitochondrial depolarization.

Authors:  Gil M Yerushalmi; Raya Leibowitz-Amit; Miriam Shaharabany; Ilan Tsarfaty
Journal:  Neoplasia       Date:  2002 Nov-Dec       Impact factor: 5.715

Review 5.  MET overexpression and gene amplification in NSCLC: a clinical perspective.

Authors:  Lorenza Landi; Gabriele Minuti; Armida D'Incecco; Jessica Salvini; Federico Cappuzzo
Journal:  Lung Cancer (Auckl)       Date:  2013-06-18

6.  Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a.

Authors:  Nikolaus Schiering; Stefan Knapp; Marina Marconi; Maria M Flocco; Jean Cui; Rita Perego; Luisa Rusconi; Cinzia Cristiani
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-14       Impact factor: 11.205

7.  Hepatocyte-specific c-Met deletion disrupts redox homeostasis and sensitizes to Fas-mediated apoptosis.

Authors:  Luis E Gómez-Quiroz; Valentina M Factor; Pal Kaposi-Novak; Cedric Coulouarn; Elizabeth A Conner; Snorri S Thorgeirsson
Journal:  J Biol Chem       Date:  2008-03-18       Impact factor: 5.157

8.  A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.

Authors:  Lainie P Martin; Michael Sill; Mark S Shahin; Matthew Powell; Paul DiSilvestro; Lisa M Landrum; Stephanie L Gaillard; Michael J Goodheart; James Hoffman; Russell J Schilder
Journal:  Gynecol Oncol       Date:  2013-12-18       Impact factor: 5.482

Review 9.  Hepatocyte growth factor and alternative splice variants - expression, regulation and implications in osteogenesis and bone health and repair.

Authors:  Rachel N Frisch; Kevin M Curtis; Kristina K Aenlle; Guy A Howard
Journal:  Expert Opin Ther Targets       Date:  2016-03-21       Impact factor: 6.902

10.  An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis.

Authors:  Marion Zillhardt; James G Christensen; Ernst Lengyel
Journal:  Neoplasia       Date:  2010-01       Impact factor: 5.715
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.